Search results for "mRNA Gene Therapy Concern"

Witness Testimony Keywords from Transcript mRNA Gene Therapy Concern, Doctor Exemption Refusal Risk, Bachelor of Science student at the University of Manitoba, she declined COVID vaccination after recalling mRNA technology being discussed in prior coursework as experimental gene therapy. She ultimately changed her degree from microbiology to a general science program, eliminating her planned

Witness Testimony Keywords from Transcript mRNA vaccine regulation, gene therapy definition, EMA exclusion pharmacokinetics requirement, lipid nanoparticle toxicity, spike protein persistence, transplacental passage concern gene therapy products and were approved without the full regulatory controls required for such products meet the criteria for gene therapy medicinal products because their effects are mediated by transferred unusually compressed, with overlapping phases and limited dose-optimization studies, and referenced concerns

, rolling review approval, EMA regulatory flags, conditional marketing authorization, gene therapy classification dispute, batch variability concerns, truncated mRNA fragments, lipid nanoparticle stability, spike protein She explained that although mRNA products meet regulatory definitions of gene therapy due to their nucleic acid mechanism of action, they were evaluated under vaccine regulatory pathways rather than gene therapy Gutschi described concerns identified in European Medicines Agency (EMA) review documents, including

Variability, Quality Assurance, Quality Control, Pharmaceutical Standards, Gene Therapy Classification , Genomic Integration Concern, Biodistribution, Spike Protein Expression, Regulatory Oversight, Vaccine Injections and Quality Control Concerns One Line Summary Molecular biologist Dr. genetic elements, and posed safety concerns based on molecular and manufacturing inconsistencies. Braden described the injections as gene therapy products rather than conventional vaccines and raised

concerns, spike protein toxicity, lipid nanoparticle delivery, biodistribution issues, immune imprinting hypothesis, regulatory oversight critique, emergency authorization process, genetic therapy classification One Line Summary Virologist presents concerns about mRNA vaccine platform design, regulatory approval concerns about the design and implementation of mRNA COVID-19 vaccines. He expressed concern about immune imprinting, repeated booster administration, and the impact of widespread

transmission not tested, crossover unblinding issue, severe adverse events increase, all-cause mortality concern , reactogenicity reporting, gene therapy classification, regulatory capture allegation, conflict of interest of the COVID-19 Response in Canada; November 2023 Main Topic Critical analysis of Pfizer’s Phase III mRNA McLeod, founder of a medical research analysis firm, presented a detailed critique of Pfizer’s Phase III mRNA She also raised concerns about abbreviated safety testing for a novel gene-based platform, including

From a marketing point of view, the most important reasons to mislabel the mRNA gene therapy products One big concern is that, unlike mRNA, DNA can integrate in the cell genome without the step of reverse experimental mRNA-LNP gene therapy injections, we concluded that: These injections did not undergo the standard approval process for gene therapy products. Immediately halt the use of experimental mRNA-LNP gene therapy injections for COVID-19 prevention.

Keywords from Transcript neurodegenerative disease research, spike protein toxicity, blood-brain barrier concerns neurological risk, precautionary principle advocacy, regulatory oversight critique, experimental platform concerns One Line Summary UBC neuroscientist raises concerns about spike protein neurotoxicity, biodistribution He stated that novel gene-based platforms should undergo rigorous independent evaluation before widespread deployment and expressed concern that safety signals may not have been fully explored prior to mass

Witness Testimony Keywords from Transcript pandemic definition change, PCR cycle threshold concerns, Barry Breger MD General Practitioner Both (Expert and Personal Experience) Witness ID: NCI-W-242 Hearing novel virus, criticized changes to the definition of a pandemic to include case counts, and expressed concerns He characterized mRNA vaccines as experimental gene therapy products and argued that emergency use authorization He cited ivermectin, hydroxychloroquine, vitamin C, and vitamin D supplementation as therapies he believed

transcripts, GMP compliance concerns, biodistribution findings, endocrine system effects, immune suppression concerns, informed consent ethics, fifth-generation warfare concept, psyops deployment allegation, messaging One Line Summary mRNA pioneer Dr. He stated that he initially viewed COVID-19 genetic vaccines with concern because they encode the SARS-CoV Malone raised concerns about manufacturing quality, alleging evidence of plasmid DNA contamination, truncated

system and concerns regarding vaccine platform safety and immunological consequences. COVID-19 vaccines as gene therapy products and alleged deficiencies in preclinical, clinical, and pharmacokinetic endpoints, statistical bias, antibody measurement timing, regulatory oversight, and data integrity concerns Concerns regarding pediatrician silence, RNA vaccination of children, media suppression of dissenting Ethical concerns regarding COVID-19 vaccination of pregnant women and children, institutional deference

These concerns are supported and further elaborated upon by findings in the November 28, 2023 NCI Report Economic Pressures : There were concerns that economic motivations, such as attracting foreign investment This is critical because long-term effects, particularly for gene therapies like mRNA vaccines, are unknown Conflict of Interest and Independence : There were concerns about conflicts of interest within Health Surveillance: Continuous monitoring of approved pharmaceuticals is essential to detect and address any safety concerns